These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16433595)

  • 1. Anecortave acetate.
    Bakri SJ; Kaiser PK
    Expert Opin Investig Drugs; 2006 Feb; 15(2):163-9. PubMed ID: 16433595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of posterior juxtascleral depot administration of the angiostatic cortisene anecortave acetate for treatment of subfoveal choroidal neovascularization in patients with age-related macular degeneration.
    Augustin AJ; D'Amico DJ; Mieler WF; Schneebaum C; Beasley C
    Graefes Arch Clin Exp Ophthalmol; 2005 Jan; 243(1):9-12. PubMed ID: 15290154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anecortave acetate for the treatment of exudative age-related macular degeneration--a review of clinical outcomes.
    Russell SR; Hudson HL; Jerdan JA;
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S79-90. PubMed ID: 17240260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anecortave acetate for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Schmidt-Erfurth U; Michels S; Michels R; Aue A
    Eur J Ophthalmol; 2005; 15(4):482-5. PubMed ID: 16001382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration.
    Slakter JS; Bochow TW; D'Amico DJ; Marks B; Jerdan J; Sullivan EK; Robertson SM; Slakter JS; Sullins G; Zilliox P;
    Ophthalmology; 2006 Jan; 113(1):3-13. PubMed ID: 16368146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes.
    D'Amico DJ; Goldberg MF; Hudson H; Jerdan JA; Krueger DS; Luna SP; Robertson SM; Russell S; Singerman L; Slakter JS; Yannuzzi L; Zilliox P;
    Ophthalmology; 2003 Dec; 110(12):2372-83; discussin 2384-5. PubMed ID: 14644721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical safety profile of posterior juxtascleral depot administration of anecortave acetate 15 mg suspension as primary therapy or adjunctive therapy with photodynamic therapy for treatment of wet age-related macular degeneration.
    Regillo CD; D'Amico DJ; Mieler WF; Schneebaum C; Beasley CH; Sullins GT
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S70-8. PubMed ID: 17240259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy.
    D'Amico DJ; Goldberg MF; Hudson H; Jerdan JA; Krueger S; Luna S; Robertson SM; Russell S; Singerman L; Slakter JS; Sullivan EK; Yannuzzi L; Zilliox P;
    Retina; 2003 Feb; 23(1):14-23. PubMed ID: 12652226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical efficacy of anecortave acetate.
    Clark AF
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S41-8. PubMed ID: 17240256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First clinical experience with anecortave acetate (Retaane).
    Hayek S; Scherrer M; Barthelmes D; Fleischhauer JC; Kurz-Levin MM; Menghini M; Helbig H; Sutter FK
    Klin Monbl Augenheilkd; 2007 Apr; 224(4):279-81. PubMed ID: 17458792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anecortave acetate in the treatment of age-related macular degeneration.
    Augustin A
    Clin Interv Aging; 2006; 1(3):237-46. PubMed ID: 18046876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anecortave (Alcon Laboratories).
    Vinores SA
    IDrugs; 2005 Apr; 8(4):327-34. PubMed ID: 15800808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging drugs for age-related macular degeneration.
    Augustin AJ; Offermann I
    Expert Opin Emerg Drugs; 2006 Nov; 11(4):725-40. PubMed ID: 17064228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of action of the angiostatic cortisene anecortave acetate.
    Clark AF
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S26-34. PubMed ID: 17240253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anecortave acetate for fibrotic lesions with presence of residual peripheral activity in age-related macular degeneration.
    Aggermann T; Haas P; Binder S
    Ann Ophthalmol (Skokie); 2008; 40(1):28-30. PubMed ID: 18556978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posterior juxtascleral depot administration of anecortave acetate.
    Kaiser PK; Goldberg MF; Davis AA;
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S62-9. PubMed ID: 17240258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anecortave acetate.
    Clarke MS
    Ophthalmology; 2004 Dec; 111(12):2316; author reply 2316-7. PubMed ID: 15582099
    [No Abstract]   [Full Text] [Related]  

  • 18. [Alternative therapies for choroidal neovessels resulting from age-related macular degeneration].
    Soubrane G; Souied E; Haddad W; Razavi S; Roquet W; Coscas G
    J Fr Ophtalmol; 2003 Oct; 26(8):876-8. PubMed ID: 14586234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug pricing for a novel treatment for wet macular degeneration: using incremental cost-effectiveness ratios to ensure societal value.
    Sharma S; Bakal J; Sharma SM; Covert D; Shah GK
    Can J Ophthalmol; 2005 Jun; 40(3):369-77. PubMed ID: 15947806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and metabolism of anecortave acetate in animals and humans.
    Dahlin DC; Rahimy MH
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S49-61. PubMed ID: 17240257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.